about
The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysisWeibel-Palade bodies: a window to von Willebrand disease.Prevalence of persistent platelet reactivity despite use of aspirin: a systematic reviewHigh levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetesState of the art: von Willebrand disease.Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation.The clinical impact of platelet refractoriness: correlation with bleeding and survival.A novel candidate mutation (Arg611-->His) in type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia.Functional architecture of Weibel-Palade bodies.Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence.Correlative light microscopy and electron tomography to study Von Willebrand factor exocytosis from vascular endothelial cells.Content delivery to newly forming Weibel-Palade bodies is facilitated by multiple connections with the Golgi apparatus.Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease.Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism.Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort.Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism.Plasma coagulation factor levels in venous thrombosis.Principles of care for the diagnosis and treatment of von Willebrand disease.Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.Determinants of increased levels of von Willebrand factor and coagulation factor VIII in patients with venous thrombosis.von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.Developments in the diagnostic procedures for von Willebrand disease.Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial.Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey.Lifecycle of Weibel-Palade bodies.Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography.Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease.Joint surgery in von Willebrand disease: a multicentre cross-sectional study.Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.Towards the imaging of Weibel-Palade body biogenesis by serial block face-scanning electron microscopy.Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand diseasePolymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
P50
Q27016555-A10E714D-2B8C-4370-A6A1-FB0C3EE4EF69Q27693255-590A8666-7691-4AF1-B40D-940C84A85C2FQ28217967-14F2F717-F5ED-4B25-812C-9F9183BCA712Q28222494-B578F90D-EB1F-4DD9-BEC0-16E67DB9CD55Q30249030-C364479F-A987-4FB9-8130-701173625392Q31077810-BE9CD000-189C-4270-8738-7662ED27A584Q33380020-5B00A94F-A1F2-4443-9B2C-B375ED1A7CBFQ33489575-FA27E460-0432-4E66-8F8E-48E5139A4E50Q34160799-0C27B056-49DC-44DD-B48F-73B625C54FD5Q35100545-4F7D1F0F-94F6-47C6-8840-8FB6C5F0B685Q35306798-0BAD183D-D10F-44CB-BD13-F82FD800A475Q35567864-AE4467E2-B8EA-4CE4-807B-3B4035BB2B1AQ35859255-FA13FAFD-A9CD-4DE3-A74C-0457D43E6799Q35987865-876E139B-D17A-4E78-88E7-73772B453999Q36322289-67BBCD94-BFC7-41D9-AF23-85A16C6AC831Q36658007-2AAD81B7-E79F-4000-A63F-19B0A9EF1978Q36715886-CF1EFDB6-91C0-49FD-883D-CC1B06B6A21BQ36791492-9439A3FF-A450-4C2C-A376-7265077BA090Q36805813-E32B768A-99A7-40D0-ADF1-51D74256E978Q36887785-E666A7A0-C5C9-4971-9564-EE72A085AF09Q36917291-F45D2366-8F1C-4083-8F27-86FD32D86107Q37376222-F896A905-B292-4CCA-99ED-62FBCC63C84CQ38413638-080B69D8-7855-4FBE-AC7A-A5C65E98AF2AQ38682256-CB4A02DD-FFD5-418C-88F5-CBE437DBAD5AQ39037761-FB084347-079E-427E-ABF4-DB5D2E57FF88Q39038099-7186D00D-D5C3-4FA2-A84C-ABA7FE1D396EQ39048674-CA306B46-85B1-4FF9-BCE6-8F7C037F4A12Q40031451-13438AC0-025C-4C95-B685-2063C2168378Q40166447-6D3B3FD7-F192-4680-8B79-C49E05FB379DQ40176994-8C662BDB-27B8-446B-A648-CE923EEB3BF9Q40287631-3A05DE41-B4CF-44C1-923A-FE5DDBCEC2E0Q40341489-AB22655E-425A-4317-A59F-9E3430D08F01Q40653035-AA1D5CC3-219C-4D0F-8537-5DE4214F55D4Q41100189-8D6DA765-F432-4C18-8F77-59F09B7FD88EQ41164496-EE032197-8D0B-4C72-BCEA-558B73EB8650Q41490144-D1608E36-7D9E-4F40-953D-F19EB63C6B2BQ41808379-21236DBB-54FC-4483-9604-516A1CBEF464Q42337433-6383D3B5-764C-4750-9DFE-ACC003358919Q42926179-56D1C897-5579-452E-A3B6-7ED616972ED0Q42937413-2F70D29A-B316-4643-9AF4-7A29679436C9
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jeroen C J Eikenboom
@ast
Jeroen C J Eikenboom
@en
Jeroen C J Eikenboom
@es
Jeroen C J Eikenboom
@sl
Jeroen Eikenboom
@nl
type
label
Jeroen C J Eikenboom
@ast
Jeroen C J Eikenboom
@en
Jeroen C J Eikenboom
@es
Jeroen C J Eikenboom
@sl
Jeroen Eikenboom
@nl
altLabel
HC Eikenboom
@en
HCJ Eikenboom
@en
Hieronymus CJ Eikenboom
@en
JC Eikenboom
@en
JCJ Eikenboom
@en
Jeroen C Eikenboom
@en
Jeroen C.J. Eikenboom
@nl
Jeroen CJ Eikenboom
@en
prefLabel
Jeroen C J Eikenboom
@ast
Jeroen C J Eikenboom
@en
Jeroen C J Eikenboom
@es
Jeroen C J Eikenboom
@sl
Jeroen Eikenboom
@nl
P1006
P214
P1006
P106
P21
P213
0000 0003 8933 4834
P214
P31
P496
0000-0002-3268-5759
P7859
viaf-282739022